Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6545064 | 0.81 | MAPT (0.43) | CA9CA14KDM4EMAPTLMNA | |
| SCHEMBL6545935 | 0.78 | GAA (0.39) | CA9MAPTLMNAMEN1KMT2A | |
| SCHEMBL6546173 | 0.74 | GABRA1 (0.38) | KDM4EMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3550152 | 0.74 | GABRA1 (0.53) | PTGDRPTGDR2KDM4EMAPTLMNA | |
| SCHEMBL6545599 | 0.71 | MAOA (0.38) | CA2MMP2MMP9MMP8MMP14 | |
| SCHEMBL6545926 | 0.68 | GAA (0.38) | CA2MMP2MMP8MMP14CA9 | |
| SCHEMBL30132473 | 0.68 | AR (0.52) | PTGDRPTGDR2KDM4EMAPTMEN1 | |
| SCHEMBL28332945 | 0.66 | ALDH1A1 (0.41) | KDM4EMAPTMEN1KMT2AHIF1A | |
| SCHEMBL6546158 | 0.65 | ALDH1A1 (0.42) | LMNAKMT2AALDH1A1HPGDGAA | |
| SCHEMBL3548978 | 0.65 | HPGD (0.49) | CA2CA9KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379533-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | Leo Pharma A/S (DK) | 2004-01-14 | — | — | EP | disclosed |
| US-6605742-B2 | Rheumatic diseases; antiarthritic agents; antitumor agents | LEO PHARMA A/S (DK) | 2003-08-12 | — | — | US | disclosed |
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | US | disclosed |
| WO-2002083696-A2 | NOVEL CYCLO AZAPHOSPHA HYDROCARBONS | LEO PHARMA A/S (DK) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177706-A1 | Novel cyclo azaphospha hydrocarbons | CMA1, MMP9, CPA1 | CA2 1491/4885MMP2 27/4885MMP9 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.